Literature DB >> 28565866

Inhibition of PKCα reduces the ability of migration of kidney cancer cells but has no impact on cell apoptosis.

Bo Zhan1, Chuize Kong1, Zhe Zhang1, Xiao Dong1, Naiwen Zhang1.   

Abstract

Kidney cancer is among the most important causes of cancer-associated mortality worldwide. The present study aimed to evaluate protein kinase C α (PKCα) expression in kidney cancer tissues and cell lines, and its significance in apoptosis and migration. Expression of PKCα was analyzed using quantitative polymerase chain reaction and western blotting. In addition, the inhibitor of PKCα (calphostin C and GO6976) was used to treat kidney cancer cells. The ACHN cell line was generated with PKCα-small-interfering RNA (siRNA) and a stable expression of PKCα, in order to facilitate the analysis of apoptosis and migration of PKCα during knockdown and inactivation. Flow cytometry was used to determine the rates of apoptosis. Immunohistochemical staining was used to identify the localization of PKCα in renal clear cell carcinoma and normal sections. PKCα expression in normal tissues was found to be greater than in cancerous tissues. Furthermore, apoptosis was not promoted with PKCα inhibitors or PKCα-siRNA treatment, and a decrease of the migration ability was observed following transfection with PKCα-dominant negative. The results indicated that inhibition of PKCα might not contribute to apoptosis progression in kidney carcinoma.

Entities:  

Keywords:  apoptosis; inhibitor; kidney carcinoma; migration; protein kinase Cα

Year:  2017        PMID: 28565866      PMCID: PMC5443214          DOI: 10.3892/etm.2017.4258

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  23 in total

1.  Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage.

Authors:  Erin E Kent; Anita Ambs; Sandra A Mitchell; Steven B Clauser; Ashley Wilder Smith; Ron D Hays
Journal:  Cancer       Date:  2014-11-04       Impact factor: 6.860

2.  Protein kinase C isozymes as therapeutic targets for treatment of human cancers.

Authors:  Alan P Fields; Nicole R Murray
Journal:  Adv Enzyme Regul       Date:  2008-03-18

3.  Ca2+ signalling in rat vascular smooth muscle cells: a role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin.

Authors:  J Fan; K L Byron
Journal:  J Physiol       Date:  2000-05-01       Impact factor: 5.182

4.  High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells.

Authors:  K Masur; K Lang; B Niggemann; K S Zanker; F Entschladen
Journal:  Mol Biol Cell       Date:  2001-07       Impact factor: 4.138

5.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  Protein kinase Cδ protects against bile acid apoptosis by suppressing proapoptotic JNK and BIM pathways in human and rat hepatocytes.

Authors:  Cynthia R L Webster; Andrea N Johnston; M Sawkat Anwer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-10-30       Impact factor: 4.052

7.  PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.

Authors:  Vesa Aaltonen; Jussi Koivunen; Matti Laato; Juha Peltonen
Journal:  Cancer Lett       Date:  2007-02-22       Impact factor: 8.679

8.  Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway.

Authors:  Yuichi Tanaka; M Veronica Gavrielides; Yasuhiro Mitsuuchi; Teruhiko Fujii; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

9.  Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.

Authors:  Huan-Tian Zhang; Dabao Zhang; Zhen-Gang Zha; Chang-Deng Hu
Journal:  Biochim Biophys Acta       Date:  2014-10-02

10.  A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.

Authors:  Tameka A Bailey; Haitao Luan; Eric Tom; Timothy Alan Bielecki; Bhopal Mohapatra; Gulzar Ahmad; Manju George; David L Kelly; Amarnath Natarajan; Srikumar M Raja; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2014-09-15       Impact factor: 5.157

View more
  3 in total

Review 1.  The complexities of PKCα signaling in cancer.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Adv Biol Regul       Date:  2020-11-23

2.  Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.

Authors:  Vladislav Volarevic; Bojana Simovic Markovic; Marina Gazdic Jankovic; Bojana Djokovic; Nemanja Jovicic; C Randall Harrell; Crissy Fellabaum; Valentin Djonov; Nebojsa Arsenijevic; Miodrag L Lukic
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

Review 3.  Targeting Protein Kinase C for Cancer Therapy.

Authors:  Sijia He; Qi Li; Qian Huang; Jin Cheng
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.